Infusion Therapies And Advanced Systems Will Shape Healthcare Outcomes
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
26 May 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$182.80
33.8% undervalued intrinsic discount15 Aug
US$120.95
1Y
-22.4%7D
11.9%